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Percutaaeous transluminal coronary angiop!arty is commonly from restcnatic ksions has dcmonstratcd urganized thrombus 
used for the trcatmeot of symptomatic coronary artery disease in -25% of lesions (7). These examples of thrombos detection 
(1) but may be complicated by the generation of a thrombus at soggcsl that activation of the clotting cascade wars in 8550 
the site of balloon dilation. Muial tlnombos formation may ciation with aogioplasty. Howwr, the aforementioned tech- 
result in &opt closure (2) sod may participate in the dcvcl- niques provide a siatic~image of thrombais Tut are therefore 
opmcnt ot intimal hyT;rrrp$sia (3,4), the pathologic hallmark of insufficient to detect whether blood clottinE was ini!iatcd 
restcnosis after arlg;oplas& before, during or after ongiapl~ty. 
Tbc presence of thmmbus cs an ear!y went after coronary 
angioplasty has been drvonstratcd by a variety of techniques, 
including angiography (5) sod angiuwpy (h). Jo addition, 
pathologic examination of atherectomy specimens derived 
By meawing pcptides that are released 82 each step of the 
coagulation caxade, it is pwible to assess the dyoamic 
biorhcmkal events that are associated with active clot fomw 
tion (8). The.. peptides include tibrinopcptidc A (9.10) and 
prothrombin fragment Fir2 (11.12). Fibrinopeptidc A is rc- 
leased from the alphachain of fibrinogen when thmmbin 
cawert~ fibrinogen to fibrin and is therefore an indicator of 
thmmbin actkity. Prothrombin fragment F,,, is released from 
the amino-terminal portion of protiuombin when it is con- 
verted to thrombin by activated factor X (Factor Xa) and is 
therefore co indicator of thmmbin generation. The plasma 
levels of these peptides arc elevated dming a&e thromlmsis 
(8). 
We hypothesized that these peptides may serve as biochem- 
kal markers of thrombosis in the setting of mrontuy balloat 
angioplasty. In this study. peptide levels were therefore mea- fadure to cbtain i.dormed consent. The protocoi was approved 
sured before an3 after coronary angiopl=ty in blood ,with- by tbi, lnrtitutional Review Board of the Mount Siwi hledical 
drawn directly from the coronary artery. The results demon- Center, and all patients gave written informed conwrtt. 
strafe that measurement of coagulation peptides from blood In contl~t to the pilot study, blood in the corocary 
withdrawn through an angiopiasty catheter is feasible and safe angioplasty study was collected at three separate times. After 
and suggest that angioplasty results io mcreased thmmbm hareline coronary angiography and before balloon inwtion, 
generation and activity in a subset of patients and that t:us the first SC, of samples (proximal to lesion bfwe ang “p&y) 
subxt is associated with a higher incidcncc of tesior. complv- was withdrawn ftom the guiding cathew positioned in the 
ity on postrmgioplasty angiography. o&m of the left main or right corona-, artery. The semcd xt 
Methods 
Pilot study. Although plasma achv~t~on peptlde lewls hare 
generally been assayed in peripheral ~cnous blood. our goosl 
was to measure them in coronary artcty blued mllectrd 
through a coronary angioplasty catheter positioned near the 
site ofballoon dilntion. A potential aduntilge cr this technique 
over Peripheral venous sampling is thst dilution of pept~de 
levels with mixed venous blood is nvolded. A potential dirad- 
vantage is that blocd withdraw1 tbrouah :I lon$. narrow 
angio&&y catheter may itself ele~ttr pla& lov&of tibnn- 
opeptide A and F,,,. Tu detemdnc the Lasibility of blood 
u&ddmwal through ai angioplny catheter, it pilo; study WIS 
therefore performed. 
The pilot study inchded six patientr treated with coronas 
angiaplasty for stable angina. All patients received adaily dose 
of 323 mg of oral aspirin. Peptide levels were compared in each 
patient by means of four sets of samples. The first set (srr I) 
wry withdrawn by venipuncturc from the right arwcubital 
fossa and the second set (set 2) by rxpirntion from the femoral 
artery sheath (USCI) (BF. 2.7~mm internal diameter. ll.S-cm 
length).both before heparinbation. After systemic intmvenous 
hepzriaization (10,000-U bolos, followed by infusion of 
1,wO U/h), at angioplasty catheter was advanced to the ostium 
of the left main or right mronary artery. and a third zet of 
samples (set 3) was aspirated through the angioplasty catheter 
(Baxter Scientific) (0.02~in. [O.S mm] internal diameter. 
135-cttt length). A mronary guide wire was not used during 
advancement of the angioplasty catheter to the ostium of the 
vewl, and therefore set 3 war collected through the balloon 
catheter lumen with no guide wire present. A final set (set 4) 
w then collected horn the left ant< cubital fossa by venipunc- 
ture. Set 4 was withdrawn immc~liitcly after set 3. The 
preheparin arterial samples (set 2) were not withdrawn 
through the angioplasty catheter because of the risk of blood 
clotting an the external surface of the balloon or within the 
catheter lumen. 
Comrmq angiopIpsty sludy. After a feasibility dctermina- 
lion, patients treated for s:able and unstable tmgina with 
coronary angioplasty at Lc Mount Sinai Medical Center 
Cardiac Catheterization. Laboratory (New York) were consid- 
ered for enrollment in tht. study. Exclusion criteria included 
acute myoc~dizl infarction, ax uf a iicd wire balloon or 
carorta~ atherectomy cathctcr, hcmadynamic instability, renal 
failure, hematocrit <34%, presence of an aortic aneurysm, 
enrollment in a thrombolytic trial for totsfable angina and 
I . 
of blood samples (distal to lesion before &!gioplasty) ans 
rithdrawn through the angioplasty catheter after the leGon 
had been crossed. before the balloon was infla:ed. to deter- 
mix bar&c Auctu-t‘ oi ons of plasma levels of fibrinop-ptidc A 
dnd F, _: mm the lesion. The coronary guide wire was 
rcowcd before withdrawal of this set and then reinserted. If a 
patient erpercenced chest pain or hemodynamic insl;lbility 
after the lesion wa crossed with the balloon catheter, the 
second set of samples was not collected. After successful 
dil;ttiu~. the wire was again removed, and the third and 
complete set of samples (after angioplasty) ws withdrawn 
through the rngioplasry catheter positioned just distal to Je 
site of the lcsian. Angioplasty was pcrformed using standard 
procedures ,ts previously described (5). 
il\ in the pilat sturly. all patients xc&cd 325 ntg of oral 
apirin and intmwtous heperin (lOJJWJ-U bolus. followed by 
infusion of I,Wt U/b) before coronary angioplasq. Before 
blood samples were drawn, tt,e actiwted clotting time was 
mwrurcd is> the catheterization laboratory using the Wemo- 
chron (International Technidyne Corporation). Throughout 
the proxxdure, the rate of intravenous heparin ws adjusted to 
maintain the activated clotting time >3W s. 
Colleclioo and processing of bled samples. All blood 
samokr were obtdtined bv two investieators (J.D.M.. P.A.M.) 
usto; precooled plastic s&es preloaded with anticoagulant 
provided by the manufxturer of the kit used for radioimmu- 
nologic determination of plasma fibrinopeptide A (Byk- 
Sangtcc, Dietzenbach, Gernmny). No heparimbonded cathe- 
ters or sheaths were used in this study. Venous samples were 
collected by merms of meticulous venipuncture using a l9- 
gsugc butt&y without a tourniquet. The first 4 ml of venou 
blood was discarded. Arterial samoles were collected from the 
femoral sheath and coronary an&plasty catheter after dis- 
carding 4 and ! ml of blood, respectively. A total of 2.7 ml of 
blood wns then withdrawn to determine the levels of tibrin- 
opeptide A and F,,, (blaodlanticoagulant ratio 0.99.1 vb). 
Aft& collrction if blood samples, plasma frncrions were 
obtained bv centrifueation at 49.Z for 20 min at 2,500 rpm 
(1.6Wg) a,.d stored at -80°C. 
Detertninnlion bf plasma activation peptide levels. Fibrin- 
opcptide A was txaured by enzyme immunoassay in plasma 
extrected wire with bentonitc to remove fibrinogen (Byk- 
Snngtec). Thir method has an interassay coefficient ofvari.ition 
of 5.4%. The plasma concentrations of F,,, were deterrained 
by double-anttbody radioimmunoassay, aspreviously described 
(12). The interassay coellicient ofvariation for this technique s 
8%. Samples were analyzed without knowledge of the clinical 
data. 
Anaioamshic analysis. Atherosclerotic lesions to be treated 
POSWIEPARIN 
with coronary angioplasty were visualized angiographically in two 
orthogonal views before and after tbe prmdure. Angi@rams 
were interpreted by two experienced angiogmphers without 
knowledge of the results of the peptide awys. Lesions were 
charactetid kfore mgioplmy as z~~nplcn or simple acmrdimg 
to Ambme et al. (13). kilns were chamcrerized after angio- 
@asty by determining the presence or absence of an&graphic 
filline defects (definite thrombusl. transluccncv (wssibfe throm- 
bes)‘dnd dis&tion (a linear radhensity adj&At lo the site of 
dilatation) (5). A nonideal lesion morphology after angioplasty 
was defined as a lesion associated with dissecrion, translucency or 
filling defects. 
Stalistical analysis. Coeflicients of skewness and kurtosis 
were calculated to test for deviations from a normal distribu- 
aft& heparinization is not know; Ti determine which batients 
tion. Because the coagulation pcptide levels were found to be 
1.73 @ml for fibrinopeptide~A’and~O.‘lf ~mol/lii~r for F,+t. 
nonnormally distributed, nonparametric statistics were used. 
exhibited a significant increase or decrease in plasma levels 
Paired data were analyzed by means of the Wilcoxon signed- 
To calculate changes in peptide levels bcforc and after nngio- 
rank test. Descriptive statistics include mean value c SD or 
phtsty (AF, tZ, AFPA), the pcptide plasma value in the samples 
between two samples, we therefore defined the upper normal 
median and 95% confidence interval (95% Cl). The normal 
range of values for plasma fibrinopeptide A and F, +1 in serial 
drawn proximal to the lesion before angioplasty were sub- 
limit ofchangc as the 95th percentile of the distribution of the 
rracted from the plasma value of the corresponding peptide 
changes between samples collected proximal versus distal to 
samples withdrawn from an angioplastv catheter in oatients 
measured in the pastnngioplasty set of samples. All tests 
the lesion before coronary angioplasty (17 patients), which was 
presented in this report were two-railed. Plasma Notide 
.. 
P@m 1. Pilot study. Serial plasma fibrkqeptide A (PA) and 
prorhrombin fragment Flr2 levelsbefore (e& 1 [a = 61 aad 2 [n = 41) 
intravenous heparin. The fibrinopeptidc A tevcls in samples 
and afler (WLS 3 ad 4 [II = 6 for both]) heparin adminisimtion. Each 
withdrawn either from the catheter or from a pxipberal vein 
SET1 
Itax connects data points &rived from the same patient. Blood was 
SET2 SET3 
after the patients received full anticoagulation with heparin 
SET4 
collected byveaipuncture (VEIN), aspiration through a femoral arteq 
were similar to those of venous samples withdrawn before 
VEtN FEM SHEATH FTCACATH WN 
sheath (FEM SHEATH) and by aspiration through an angioplasty 
catheter IPTCA CATHI. 
catheterization and heuarin administration (set 3. median 
concentrations for a group of patients were deemed’si&ft- 
cantly different from a reference group when both the median 
was outside the 95% Cl of Ihe referesce group and p < 0.05 
(14). 
Results 
Pilot study. The plasma levels of the activation peptides 
from the six patients enrolled in the pilot study are shown in 
Figure I, in which each tine connects data derived from an 
individual patient. Sets I, 3 and 4 include peptide levels 
derived from all six patients. Set 2 includes data from four of 
the six patients. Compared with venous blood collected by 
venipuncture (set I), preheparin fibrinopeptide A levels were 
significantly elevated in arterial blood withdrawn through the 
femoral sheath (set 2) (median 5.1 @ml 195% Cl 2.2 to 13.71 
vs. 32.S ndmt 195% CI 19.3 to 4X2], rcspcciively, p < 0.05). 
fibrinopeptide A or F,+? leve’s &as observed between samples 
This artifactuat elevation in plasma fibrinopcptide A concen- 
obtained by vcnipuncture and samples obtained through the 
cororxq angioplasty catheter (set 3 YS. 4). There &e~ations 
Tbe plasma levels of F,,* varied minimally as a function of 
the sampling conditions. Blood withdrawal through the arterial 
sheath before hcparin (set 2) resulted in a small, statistically 
insignificant arlifactual elevation of F,,l levels (set 1, median 
0.93 nmoUliter 195% Cl 0.69 to 3.q vs. set 2. median 1.54 
tunobliter 195% Cl 0.96 to 3.10], p = NS). This elevation was 
eliminated by the immediate systemic administration of hepa 
rin. The concentration of F,,: in postbeparin angioplasty 
catheter blood lsct 31 was similar to the veniouncture samdes 
before (set I) and after (set 4) hcparinization (set 3, meiiaa 
0.92 nmoliliter [9S% Cl 0.58 to 2.491: set 4, median 0.94 
nmoUliter 195% CI 0.67 to 2.711, p = NS). 
After hemrinization no sianificant differems in either 
25 @ml [95% CI 1.5 td 4.61; set 4, median 2.8’nglmi[95% Cl 
1.5 to 14.91; set 3 and set 4 vs. set I, p = NS). 
tration wds completely inhibited by the administration of support the feasibility of accurately measuring the levels of 
technical staff (n = 7). systemi~dixase (n = 5). age >8lJ &n 
(n = 4). failure to otltain informed consent In = 3). inabilitv to 
&w. the lesion with il balloon (n = I) and ptescncc it :I 
tlturacoabdomioal aneurysm (n = I). The remaining ?‘I pa 
tientswere enrolled in the study. In three patients the levcis of 
fibrinopeptide A after coronary nngiophsty were >?O ng’ml. 
These patients were excluded from the anslysir becnusc wch 
levels are likely to represent artifacts and to intcrfcrc with the 
accurate measutement of FlrL (unpublished date). Thw the 
study included 26 patients (metn [+SD] age S7 2 I? years: IO 
men, 7 women). 
Twenty of ihe 26 patients had il diagnosis of unst;lblc 
angina. Of these 20.9 hnd crescendo cxertiontd angm~a (C:ux~- 
dian C;lrdiovascular Society class III). Y hdd erpcricnccd rc\t 
pain (class IV). and 2 had resC pain after a mvocatdial 
mfarctmn wiihm the prwiaus month: All patients a& rr:ated 
wih oral aspirin (minimal dose 32S mg on the day of cotonaly 
angioplasty). Patients with rest pain were treated with intraw 
now heparm that was stopped -2 to 3 h before anpioplasty. 
Cix~&viur peptk!e i&s. In all 26 patients. blood samples 
wte collected proximal to the lesion before angioplosty and 
distal to the lesion after aneioulastv. In I7 of these patients. 
samples were also collected”be~~re’ballaon inflation ‘with the 
angiuplasF catheter positioned distal to the lesion. Results 
from these 17 patients ate sumtnatized in Table 1. Before 
dngioplasty. the plasma levels of tibrinopeptide A and F,,, 
melrsured proximal to the stenosis wete statisticnlly indirtin- 
guhablc iront those measured distal to the stcn~sis. Corn- 
pered wth sampler collected distal to the lesion before angio- 
pkwt?. samples collected after angioplasty dcntosstrated a 
stgmfic.w mcre~se in F,,_ I loels (median 0.45 nmolliter 195% 
Cl 0.39 to 0.561 vs. median 0.57 nmolfliter (925 Cl 0.46 to 
07S]. rcspccriveiy. p < 0.05). 
Fur all 26 study patients. tbc individual chnngs in FL+? and 
fihrin~pepnde A plasma lewls during coronq angioplasty ore 
?huw m Figure 2. Compared with the lewls seen before 
at~sio~l:~stv (orwimal to lesion). &ma level> of F,_, ah 
tu (IL?]. ~qxctivcly. p = O.Wl). In contrast. the plasma 
tibrinopcptidc A levels before angioplarty (proximal to Icsion) 
wx cm~dar to those found after the procedure (median 2.0 
ngcml [W”; Cl 1.3 to 2.21 vs. median 18 ~&III [9X Cl I.3 to 
3 O]. p = NSI. 
Figure 2 demottstates that although the overall changes in 
plitsma F, i: and fibrinopeptide A are minimal, there are a 
numhcr of individual pnticnts in whom a marked elevation in 
peptidr levels is apparent. Because the normal range of values 
tar our patients is unknown, yle used data from the sngioplasty 
.a 
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study 10 d&c as significant (for an indiitdual patient) an 
increase in F,,, > 0.11 nmoliliter and fibrinopeptide A > I.73 
@ml (see Statistical analysis). Of the 26 study patients. seven 
(27%) and five (19%) had a significant increase in plasma F,,, 
,and fibrinopeptidc A levels, resp&vely (Fig. 3). Of the seven 
patients with an elevation in plasma F,,,, tiw hrd a concorn- 
itant increase in plasma fibrinopcplide A In two patienu, an 
isolated increase in plasma F l+l occurred without an increase 
in plasma tihrinopeptide A. No elevations in tihrinopeptide A 
wcuued in the absence of an increase in plasma F,+2. Peptide 
levels in patients who had increased plasma kvels of fibrin- 
apeptide A or F,,,, or neither, are shown in Table 2. 
For the 26 study patients, a significant correlation was 
found between the changes in p!ssma tibrinopcptidc A and 
F,,, levels before and after curonnry angiopksty (r = OS, Q c 
CtJl) (Fig. 3). 
As shown in Figure 2, IS patients had a decrease in plasma 
fibrinopeplide A after angiopksty. A significant decreaw in 
plasma tibrinopeptide A (1.73 @ml) (see Statistical analysis) 
occurred in only two of these patients (Fig. 3). 
Adquay ofheprdmim. The degree of anticoagulatian 
by heparin was awssed by measuring the activated clotting 
time (see Methods). In all patients an activated ohing time 
ZMO s was documented before bled was drawn for plasma 
peptide analysts. For all patients in the coronary angioplasty 
study, the mean activated otting time was 398 + 67 s (range 
303 to 610). Activated clotting time in the 7 patients with a 
significant increase in plasma 6,+2 was not d&rent from that 
in the remaining I9 patients (418 z 63 vs. 392 ? 69 s, p = NS). 
Similarly, activated clotting time in the 5 paths with a 
sipnificanl increase in plasma fihrinopeptide A did not differ 
f&n that in the remain&g 21 patknb’(4bS 2 59 ys. 397 + 71 s. 
p = NS). 
No correlation was found between activated clotting time 
and change in tibrinopeptide Am between activated clotting 
T~;an; change in F,,, (I = 0.05 and I = O.WI. respectively, 
Awiwwftic result and mimion to coaeukcion twfide leek 
Sur&f;l -&nary angioplasty, as &fined &.a residual 
stenosis <SO%, was achkved in all patients. P~~tanaioolz~~ 
angiography revealed that 16 patie& had a nonide> &ion 
morpholqy (d&&n in 7, translucent lesion appearance in 
7. tilling defect in 2). Tixsc characteristics were absent in the 
remaining 10 patients. A greater increase in Flrz kvek afier 
angioplwty occurred in patknts with a nonf&ai lesion mm- 
phology (median iwrease 0.07 ma&liter 195% Cl 0.03 to 
0.161) than in those with a more desirabk ksiin morphology 
(me&an increase 0.02 nmobliter (95% Cf 0.00 to O.O$, p 2 
0.M) on postangjopksty angkgrapby. The median imreaw in 
Sbrinopeptide A was not significantly diUcrent between rhe 
two groups (-0.3 @ml 195% Cl -1.5 to 2.61 vs. -0.2 @ml 
[95% CI -0.4 to 0.41, resp+ctively). 
A nonideal lesion morphology on p~~tan&plasty anpiop- 
raphywns seen in 6 of the 7 patientswith a significant increase 
in plasma F,+a (vs. 10 of the 19 with no inctww in plasma 
Ft,,) and in 4 of the 5 patknts with a significanl increase in 
plasma fibrinopeptide A (vs. 12 of the 21 with nn increase in 
plasma fibrinopepride A, p = NS for borh groups). 
Rcirrtion of congularion pepride heIs to chicul ytdmmur 
andprewngiopbs~ on@ogmphrc lesion n~orpholo~. Neither the 
presenting clinical syndrome (i.e., unstable vs. stable m:mn. 
iwt vs. ewrion$ pain) our the prcangmpinsty angiosrraphtc 
ksion morphology (1.e.. complex vs. sample) was found to be 
asxxiated with sipificsndy greater or lssscr baseline plama 
levels or chances in plasma levels of F, *. or fihrinooeptide .a. 
Baseline levels and fhanges in plasma g,_: Lw!s IV&; simi!sr 
in the I I patients with and the I5 patients without rest pdin 
(rest patn prerent. median baseline F,+? 0.46 nmol;litcr (Y?ri 
CI 0.36 to MY], median change in F,_? 0.0-1 nmoL’liter !92? 
Cl O.Cdl to 0.171; rest pain absent, medran bdreline F, r2 r .I9 
nmolAiter [95% Cl D.37 to 0.651, median change in F, ,> L .U 
nmoWiter [YSJ Cl 0.01 to 0.161. p = WS). Thwi: ws a dlghti) 
greater increase in plasma Bbrinopeptidc A levels in padam 
with than without rest pain (IFS, oain oresem. nrdian chnnw 
in tibrinopeptide A O.?ng/ml [95& Ci I.4 to 5.61: rest &n 
absent. median change in FPA -0.3 ngml [W;. Cl -0.Y IO 
1.41, p = NS). 
A mmplex lesion morphology on prcang!oplasty angiogm- 
phywaspreseot in seven patients, &e (71’6) afwhom had rat 
angina. &line plasma levels and chmges in plasma lcvclr of 
F,,? and tibrinopeptidc A wrc not stgniiicantly diBercnt in 
oatienls with vetxw thaw without a mm&s lesiun tnorohoi- 
&y (mmplex morphology prcscnt. tttedi;o baseline F, .~tl.-lh 
nmoliliter 195% Cl 0.31 to 0.651. median change in F, tl 0.08 
nmol/liter [95?6 Cl 0.04 to O.JIj. mcdkm haselinc fibrinopep- 
tide A 3.7 rig/ml [95% Cl I.0 to 5.91. median change in 
tihritwpeptide A -1.1 ndml [Y5% Cl -2.2 to 6.11]: sample 
morphology present, median baseline F, +: 0.48 nmolllitcr 
[95% Cl 0.37 to O.Kl]. median change in F,,, 0.113 nmol/litcr 
195% Cl 0.01 to 0.091. median hassclinc fibrinopeptidc A 
1.5 @ml 195% Ct I.1 to 2.51. median cllangc in lihrinopeprtdc 
A -0.1 @ml [95% Cl -0.X to LO], p = NS). 
plasma F, , was seen onhi in samples collected .:ftsr balloon 
&&on &J not in samples collecied after crassisg the lesion 
but before balloon inflation, the generation of thrombin was 
nut likulg caused by ballocn-mediated plaque injury. Addi- 
tional wider&c that the incrcilx In plasma F, &, was related to 
plxque zn~u~ s provided by the oh&;iou tbairhe changes m 
F, 2 levels were greater in arteries trwt demonstrated hec- 
don. transiwncy or tilling defects on postangioplasty angiog- 
raohv. These aneiozraoh;c mcmholoeies have been associated . _ _ . 
ulth plaque disroption and th;omb&is in both human rmd 
cwrimc!~t~~I models of vessel inks M3.35.lYi The associa- 
rid” of grcatcr increases in plas&~‘F;+~ with these morphol- 
ogles suggere*rs that plasma F I+2 may provide n marker for 
intracorooary thrombosis during angioplastv. 
Ths pcncration of thrombin may hwe important impliw- 
~zons ir> the vascular reqonse to inimy. independent of it: 
rlctiuty oo librinogen. Thrumbin is-a .potcnt’ stimulant for 
~lldteler~ to wuc~~tc and dwrmtulutc ;10-2;. lo cu!turcd 
&cuinr wooth &clc. throkbin r&as a growth factor. 
actkating maoy of the growth-rclatcd gcncs and inducing 
cc:luJBr h!pcrtrophy (23.24). Thromhin may therefore panici- 
pntc in the development oi intimol hyperplaria nd restcnosis 
by it< ability to stimukne bmooth moscle prolifemtion, bath 
directly through its cffwa oo gate e~prcssion and indircctly 
through tts cCcts on platelet ;tccumulation. In the ahscncc of 
cndothelium. thromhin acts as d uasoconstrictor (251 and mw 
Discussion 
The pathologic event that underlies the clinical ~yndronrcs 
of ttnstahlr angina nod myocardial inhrction is the disruption 
of an sthcrosclsmtic plsquc in association with n superim- 
posed thrombus (15). Moon angioplasty results in p&w 
fracturing and disxction (16) and thcrcforc provides s mowI 
to study the events r&o&ted with coroow ~laoue ruotmc. 
~ , 
thcroforc play ii role in coronmy vasospasm after angiopl&. 
Although plasma lihrinopcptide A levels increased sigoifi- 
c;mtly m 8 numhcr of individual patients. no significant change 
occurred in the overall group. This may reflect oo inadequate 
sunpl~ size or the known ability of heparin to inhihit the 
gencrotion of lihrinopeptidc A in the presence of thromhm 
(IO). Thr tw patients in whom plasma fihrinopeptidc A did 
not inmxse despite nn increase in plasma F,,: may represent 
an endmplc of the greater inhibition that hcparin ercrra on 
thromhin ;activity than it does on Factor Xa activiry (lb). 
Alternatwly, the amount of thrombin generated after plxquc 
disruption in certain cases may he insufficient to result in tihrin 
formation. cvun in the absence of hepnrin. In evev patient in 
whom an increw in plasma fihrincpep:idc A did occur, n 
concomitant incrcax in Ft,, ~1116 drcumented. This sweats 
that the incrcasc in plasma fihrinopeptide A levels seen itt 
individusl patients ws not an artifact but rcprcxntcd new 
thrombin generation. 
Heturin inhibits thrombin activity and hip been chow to 
In iis chronic. stable state the ~thrro&cro;ic &q~tc is rcduci thr generation of fihrinope~tide A when addrd to 
cowed with a nonthmmbogenic ndothelillized libroua up. human hlood (IO). Results of the pilot study demonstrate that 
Disruption of this cap permits circuhdtng blood to come mto heparin inhibits the increaSe in fihrinopeptide A that occus 
contact with promagulanl elements within the plaque. such its during blood withdrawal through an arterial catheter (see 
mllagen aad tissue factor (17). This sequence of watts has Rwlts). Patients in whom an incrwe in plasma fibrmapep- 
been wanted to be in part resrnmsibk fur the development !i?e A !e\*els was ubsjsrxd aficr ansioplosty could therefore 
of thrbmbosis in atheros&rotic~c~cIs (IQ. represent a subgroup in which an inadequate dose of heparin 
The changes in coronary plasma Ft r2 reported in this study was administered. To ensure that the coronary angioplasty 
demonstrate that the generation of thrombin within the coro- study cohort had adequate anticoagulation. all patients were 
nary anety is detectable in a substantial portion of patients treated with a dose of heparin sufficient to maintain the 
tmdergoittg coronaty angioplasty. Because an increase in activated clotting time >300 s, which is a level that has been 
associated with a low incidence ofboth thrombotic losu~ and 
major in-hospital complicatioos (27.28). Compared with pa- 
tients with no significant increase in plasma peptide levels, 
patients with a significant increase in plasma levels of F,,, or 
fihrinopeptide A had a similar prolongation of activated clot- 
ting time. Furthermore, there was no correlation between the 
changes in plasma peptide levels and activated clotting time. 
These findings suggest hat the chqes in F,+* or fibrioopep 
tide A plasma levels after angioplasty were not caused by 
variations in the degree of heparinization. 
The inhibitory effects of heparin on thrombin activity may 
in part explain why a decrease in fihrioopcptide A was seen io 
o num’ber of patients (Fig. 2). In patients with tbrombophlehi- 
tis and elevated plasma tibrinopeptide A, intravenous heparin 
has been shown to markedly suppress plasma fibrinopeptide A 
levels within 15 vlin of initiation of infusion (9). The reduction 
io plasma librioopeptide A seen in some patients in the 
angioplasty study may therefore roprerent a case in which the 
propensity for arterial balloon dilation to generate thrombin 
was overshadowed by the systemic inhibitory e5ect of heparin 
on thrombin activity and fibrinopeptide A generation. 
Stody limit&mr. Previous clinical (29) and experimental 
(50) studies suggest hat thrombosis after vessel injury is a 
timedependent pheuomenon. In a study of 459 patients with 
unstable angina (5). only 4.5% were found to have a definite 
tilling defect at the site of coronary angioplasty consistent with 
thrombus at angiography 1 min after aogioplasty. On repeat 
coronary ongiogmphy performed 15 min later, 15.9% of pa- 
tients had evidence of thrombus formation. Because in the 
present study samples were withdrawn early after successful 
balloon dilation, a later undetected increase in plasma fibrin- 
opeptide A may have occurred. 
Activation of the coagulation cascade is o stofaceatalyzed 
event (31) that in the setting of sngioplasty oceors on a 
damaged vessel wall. Coagulation peptides cleaved from dteir 
parent zymogeo ore likely to bc found at a high concentration 
close to the site of injury and to be rapidly diluted by opstresm 
ttrterial blood. Although we sampled corooary blood with the 
coronary angioplasty catheter in close proximity to the site of 
dilation, the catheter is a coaxial device with a tip that is 
designed to remain in the center of ihe arterial lumen. It is 
possible that more highly significant changes in F,+2 and 
fibrinapeptide A levels did oucor, but only in the immediate 
vicinity of the dilated plaque, in weas close to the vessel wall 
that were inaccessible to the sngioplasty catheter tip. 
In contrast o the pilot study, in which blood was withdrawn 
almost immediately after iaroduction of the coronary angio- 
plasty catheter in the patient, the angioplasty study involved 
blood withdrawal through o catheter that had resided in the 
patien: for the duration of the procedure. Etecause activation 
of the clotting cascade is a time-dependent process (29), the 
increa%s in peptide levels observed in the angioplasty study 
may have resulted from artifactual activation of the clotting 
cascade within the catheter lumen or on the coronary guide 
wire. To minimize this possibility, the guide wire was removed, 
and the first milliliter of blood withdrawn through the at&- 
p&y catheter was discorded before the samples were col- 
lected (see Metbods). Ihe angioplasty catheter material did 
not appear to pmsess potent tbmmbageoic properiies because 
an ittcreas~ in brinopeptide A levels was not seen in all cases, 
and no milaossopic clots were detected on inspection of the 
guide wire or during blood withdrawal. 
Impiiatkna This study demonstrates that balloon dila- 
tion of coronary artery steooses indow thmmhin generation 
in a subgroup of patients treated with coronary aogioplasty. 
The exlettt of ?Jds induction appears to be related to the extent 
of vasctdar injury as assessed by angiography. In a certain 
proportion of cases, there is an awciated generation of fibrin, 
sow:sting that more potent inhibitors of thrombin may have a 
role in prwettting angiopl~ty-induced activation of the hema- 
static system. Fonher studies will be needed to determine the 
short- and long-term implications of thmnbin generation and 
activity during aogioplasty. 

